Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.48 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.48 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9767845 | 0.75 | FERMT2 (0.47) | NR4A2SOS2FERMT2CYP1A2CCR1 | |
| SCHEMBL7896777 | 0.72 | NR4A2 (0.47) | NR4A2SOS2FERMT2CYP1A2CCR1 | |
| SCHEMBL7835332 | 0.71 | NR4A2 (0.70) | NR4A2FERMT2CYP1A2CCR1TAAR1 | |
| SCHEMBL5275609 | 0.71 | NR4A2 (0.56) | NR4A2SOS2FERMT2CYP1A2CCR1 | |
| Hydrochloric Acid SCHEMBL7835555 | 0.70 | NR4A2 (0.68) | NR4A2FERMT2CYP1A2CCR1TAAR1 | |
| SCHEMBL9542819 | 0.69 | NR4A2 (0.43) | NR4A2SOS2FERMT2CYP1A2CCR1 | |
| SCHEMBL24420728 | 0.68 | NR4A2 (0.58) | NR4A2SOS2FERMT2CYP1A2CCR1 | |
| SCHEMBL4365534 | 0.67 | FERMT2 (0.55) | NR4A2SOS2FERMT2CYP1A2CCR1 | |
| SCHEMBL27466148 | 0.67 | NR4A2 (0.54) | NR4A2SOS2FERMT2CYP1A2CCR1 | |
| SCHEMBL9541547 | 0.67 | NR4A2 (0.54) | NR4A2SOS2FERMT2CYP1A2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296237-A1 | Use Of Chloroquine To Treat Metabolic Syndrome | UNIV WASHINGTON (US) | 2013-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296237-A1 | Use Of Chloroquine To Treat Metabolic Syndrome | NPC1L1, ECHS1, PCSK9 | NR4A2 3782/4885SOS2 4347/4885FERMT2 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.